Latest Investor Relations News

Temas Resources is on track to fully commission its Ontario metallurgical lab by July 2026, initiating large-scale testing of La Blache project material to refine its proprietary RCL technology and support commercialization.

Vitasora Health Limited has secured $4 million in a strongly oversubscribed placement, anchored by a $3 million cornerstone investment from private investor Bob Peters. The capital boost supports rapid growth in monthly billings and funds the company through expected cashflow breakeven in the second half of 2026.

Northern Star Resources acknowledges activist investor Elliott's stake and proposals, confirms ongoing CEO recruitment, and highlights progress on key projects while rejecting a sale process.

FirstWave Cloud Technology acknowledged the material nature of cash and revenue figures disclosed during a shareholder webinar and affirmed compliance with ASX continuous disclosure rules, while committing to improved timing of market announcements.

GCM Corporation is seeking shareholder approval for a 15-to-1 share consolidation as a strategic step towards a potential listing on a US national stock exchange, aiming to boost international capital access and market visibility.

Atlas Arteria has lodged its second supplementary target's statement, maintaining its firm recommendation to reject IFM’s conditional takeover offer despite an extension of the bid period to 18 June 2026.

Westpac Banking Corporation has updated details for its six-month interim dividend, confirming a fully franked 77 cents per share payable in June, alongside a Dividend Reinvestment Plan participation rate of 13.9%.

Tetratherix Limited (ASX:TTX) has launched a $2 million share purchase plan offering eligible Australian and New Zealand shareholders the chance to buy shares at a 2% discount to recent trading prices. The non-underwritten SPP opens on 4 June and closes on 18 June 2026.

Careteq Limited’s strategic investor Antanas Guoga has converted all his convertible notes into shares, wiping out the company’s convertible debt and simplifying its capital structure ahead of its AI healthtech growth push.

Dotz Nano has pushed out the maturity dates on its convertible notes to March 2027, securing continued backing from Mercer Street Capital. The move introduces new conversion limits and an option for cash settlements, signalling confidence in Dotz’s carbon capture ambitions.

The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.

Paradigm Biopharmaceuticals has successfully raised $21.375 million through an oversubscribed Share Purchase Plan and a recent placement, bolstering its balance sheet ahead of key Phase 3 trial milestones.